AMTB vs EQBK
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
AMTB presents a stark contrast between attractive valuation and deteriorating fundamental health. While the stock trades below its Graham Number ($27.18) and Intrinsic Value ($41.89), the Piotroski F-Score of 2/9 indicates significant weakness in financial health. Strong year-over-year earnings growth (57.10%) is offset by sluggish revenue growth (3.30%) and a highly bearish technical trend (10/100). The company is essentially trading at book value (P/B 0.99), making it a value play with high fundamental risk.
EQBK presents a stark contrast between fundamental health and market expectations. The deterministic health baseline is weak, highlighted by a Piotroski F-Score of 2/9, indicating significant deterioration in financial strength. While the stock trades at a substantial premium to its Graham Number ($32.33) and Intrinsic Value ($8.26), it is supported by a consistent track record of earnings beats and strong revenue growth (33% YoY). The massive discrepancy between the current P/E (38.42) and Forward P/E (8.61) suggests the market is pricing in a major earnings recovery that has yet to fully materialize in the ROE (3.44%).
Compare Another Pair
Related Comparisons
AMTB vs EQBK: Head-to-Head Comparison
This page compares Amerant Bancorp Inc. (AMTB) and Equity Bancshares, Inc. (EQBK) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.